To sum up, these mechanistic pathways align with the observed biomarker shifts and support clinical plausibility: in T2DM, dual improvements in glycemia and atherogenic lipids address two major, independent determinants of cardiovascular risk; in NAFLD, lipid lowering (particularly TG and LDL‐C) and improved insulin sensitivity are expected to reduce the high burden of cardiovascular morbidity that exceeds liver‐related outcomes in this population [51, 52]. This evidence concerns the gene INS and type 2 diabetes mellitus.